The diagnostic value of soluble death receptor 5 in ARDS

Backgrounds: Apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor 2 (also called death receptor 5, DR5) is found to be involved in the pathogenesis of ALI. However, their clinical roles in ARDS remains unclear. Methods: This clinical study was approved by ethic committee. ARDS patients were enrolled following Berlin definition, and control subjects who were not diagnosed with any pulmonary disorders were recruited. Then serum and bronchoalveolar lavage fluid (BALF) levels of soluble TRAIL and DR5 were detected using human magnetic luminex assay. Statistical analysis were performed to explore their roles. Results: In total, 56 ARDS patients and 30 control subjects were included. Both BALF and serum levels of DR5 in ARDS patients were higher than those in control subjects (73.21±77.08 vs. 4.02±3.29 pg/mL, p Conclusions: Circulating and BALF DR5 exhibited diagnostic potentials in ARDS, implying them as the biomarkers of ARDS. Grant No: NSFC 81470236 and 81670038.